Next Article in Journal
Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1
Previous Article in Journal
The Influence of Palmatine Isolated from Berberis sibirica Radix on Pentylenetetrazole-Induced Seizures in Zebrafish
Previous Article in Special Issue
Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis
Open AccessReview

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

1
Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy
2
Gastroenterology Unit, Duilio Casula Hospital, AOU Cagliari, 09042 Cagliari, Italy
3
Department of Medical Science and Public Health, University of Cagliari, 09124 Cagliari, Italy
4
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20135 Milan, Italy
5
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20135 Milan, Italy
*
Author to whom correspondence should be addressed.
These authors equally contributed.
Cells 2020, 9(5), 1234; https://doi.org/10.3390/cells9051234
Received: 26 April 2020 / Revised: 12 May 2020 / Accepted: 13 May 2020 / Published: 16 May 2020
Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host−microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner. View Full-Text
Keywords: inflammatory bowel diseases; gut microbiome; live biotherapeutic products; FMT inflammatory bowel diseases; gut microbiome; live biotherapeutic products; FMT
Show Figures

Figure 1

MDPI and ACS Style

Amoroso, C.; Perillo, F.; Strati, F.; Fantini, M.; Caprioli, F.; Facciotti, F. The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. Cells 2020, 9, 1234.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop